Africa’s pharma markets are defined by volatility, uncertainty, complexity, and ambiguity — the VUCA acronym that consultants use and operators live. But the companies that thrive in these conditions are not the ones that avoid the complexity; they are the ones that build commercial models specifically designed to operate within it. Here is what that looks like, and why the VUCA environment is as much an opportunity as it is a risk.
Currency devaluations, regulatory framework changes, political transitions, supply chain disruptions, health authority restructuring — these are not exceptional events in African pharma markets. They are the operating environment. Companies that treat them as one-off risks to be mitigated are constantly behind the curve. Companies that design for volatility — with flexible commercial models, scenario-tested pricing architectures, and distribution structures that don’t collapse under a single point of failure — are the ones that sustain performance across the cycle.
The VUCA label is often used to explain poor performance. In the hands of experienced African pharma operators, it is more useful as a design constraint: what does a commercial model need to look like in order to perform when conditions are predictably unpredictable?
Full article coming soon.